Xeris Biopharma Holdings, Inc.
XERS
$5.99
-$0.09-1.40%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -79.84% | 1,684.38% | 132.21% | 79.09% | -80.32% |
| Total Depreciation and Amortization | 0.41% | 0.25% | 0.79% | 0.67% | 0.32% |
| Total Amortization of Deferred Charges | 2.66% | 2.73% | 2.80% | -2.84% | 2.43% |
| Total Other Non-Cash Items | -21.47% | -31.02% | 52.62% | 12.72% | 23.25% |
| Change in Net Operating Assets | -61.66% | -106.08% | 189.16% | 25.53% | -1,849.58% |
| Cash from Operations | -50.76% | 8.74% | 10,027.47% | 101.81% | -607.90% |
| Capital Expenditure | 2.40% | -369.01% | 74.55% | -2,046.15% | 94.09% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 2.40% | -369.01% | 74.55% | -2,046.15% | -100.13% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 542.07% | -91.11% | 695.12% | -62.93% | 761.88% |
| Repurchase of Common Stock | -1,005.00% | -222.18% | 44.42% | 89.25% | -4,718.07% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -3,222.18% | -101.92% | 1,370.28% | 130.03% | -888.19% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -96.36% | -39.64% | 3,711.95% | 106.41% | -206.39% |